Jean Frédéric Blanc

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text

Medicine, Oncology, Pharmacology +12

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Cytokeratin 7 and 20 Expression in Cholangiocarcinomas Varies Along the Biliary Tract But Still Differs From That in Colorectal Carcinoma Metastasis

Anne Rullier, Brigitte Le Bail, Rabia Fawaz et al. · The American Journal of Surgical Pathology · 2000 · 211 citations

Medicine, Oncology, Pathology +15

PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases

Jie Yang, Eric Trépo, Pierre Nahon et al. · International Journal of Cancer · 2018 · 131 citations

Medicine, Genetics, Molecular Genetics +17